Ocular pharmacokinetics and toxicity of nanoparticular acetazolamide: In vivo distribution and safety of PHBV-ACZ nanoparticle

• Published in: International journal of pharmaceutics Vol. 645; p. 123336
• Main Authors: Erdal, Ebru, Bakici, Caner, Arslan, Aslıhan, Batur, Barış, Yaman, Mehmet Emrah, Alçığır, Mehmet Eray, Akyol, Mesut, Ekim, Okan, Salih, Bekir, Uğurlu, Nagihan
• Format: Journal Article
• Language: English
• Published: Elsevier B.V 15.10.2023
• Subjects: Acetazolamide; In vivo toxicity; Nanoparticles; Pharmacokinetic; Poly(3-hydroxybutyrate-co-3-Hydroxyvalerate); Rabbit eye; Rabbit eye; UPLC-MS; DRP; Acetazolamide; PHBV; CAI; IOP; PHBV-ACZ NP; Pharmacokinetic; MTBE; Nanoparticles; In vivo toxicity; Poly(3-hydroxybutyrate-co-3-Hydroxyvalerate); ACZ; PVA; ERG; DME
• ISSN: 0378-5173; 1873-3476
• DOI: 10.1016/j.ijpharm.2023.123336

[Display omitted] •Controlled release of ACZ by loading to PHBV nanoparticles.•In the pharmacokinetic study, ACZ was found in the highest concentration in the vitreous and retina.•ERG measurements were performed for in vivo toxicity of PHBV-ACZ NP. Diabetic macular edema (DME) is defined as fluid accumulation in the macular region, between the retinal layers, due to many diseases, especially diabetes. DME is one of the major complications of diabetic retinopathy (DRP). Carbonic anhydrase inhibitors (CAI) are a pharmaceutical agent used in different fields, especially glaucoma treatment. Acetazolamide (ACZ), which is a CAI, is an active substance that has been used off-label for many years in the treatment of macular edema due to diabetes and many other diseases. The low solubility and bioavailability of ACZ limit its use in the treatment of DME. In this study, a nanoparticulate formulation was developed that would increase the solubility and bioavailability of ACZ and allow it to be administered intravitreally. ACZ was loaded on poly(3-hydroxybutyrate-co-3-Hydroxyvalerate) (PHBV) nanoparticles and the loading efficiency was 71.58 ± 1.22%. Toxicity of nanoparticles after intravitreal application was evaluated with anterior segment and posterior segment examination findings, intraocular pressure (IOP) measurements and electrophysiological tests. At the end of the 3-month follow-up, electroretinography (ERG) measurements demonstrated that ACZ loaded PHBV (PHBV-ACZ) nanoparticles did not cause loss of function in retinal cells. On histological examination, rare degenerative changes were observed in several cell groups. In addition, pharmacokinetic studies were performed to determine the tissue distribution of ACZ at various periods. ACZ was identified in vitreous humor and retina at the highest concentration. Based on our results, the prepared nanoparticle formulation can release long-term CAI for DRP therapy and accordingly can reduce the need for monthly intravitreal injections.